NorthWest Biotherapeutics Inc (NWBO)

[meirluc]

Entropic_Squirrel, if you were trying to make an independent comparison of the 65 crossover patients to the ECAs and the 35 non-crossover patients to the same ECAs, you would obtain confounding results because of the 99 placebos, the 64 crossovers constitute the more robust patients whereas the 35 non-crossovers constitute the less robust patients. Therefore, neither group can be separately compared to the rGBM ECAs.

However, taken together as an "intend to crossover group", the group of 99 can be compared to the ECAs. At 24 months from randomization (27.1 months from surgery), The overall survival curve (fig.2) of the 2018 JTM article estimated that about 39.9% of the 331 patients or 132, were still alive. According to the MAY 10 NYAS presentation, 81 of those patients were in the treatment group. Consequently the remaining 51 survivors were in the 99 patients "intend to crossover group" (81+51=132). It is easy to see that 51 of 99 alive at 24 months translates into an mOS of roughly 24 months. Not bad for a group where more than 1/3 were non crossover patients. Kudos to the crossover group.